BETAKLAV 400 mg/5 mL+ 57 mg/5 mL prašak za oralnu suspenziju Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

betaklav 400 mg/5 ml+ 57 mg/5 ml prašak za oralnu suspenziju

krka farma d.o.o. sarajevo - amoksicilin, klavulanska kiselina - prašak za oralnu suspenziju - 400 mg/5 ml+ 57 mg/5 ml - 5 ml suspenzije sadrži: 400 mg amoksicilina (u obliku amoksicilin trihidrata) i 57 mg klavulanske kiseline (u obliku kalijevog klavulanata)

CLAVIUS 875 mg/1 tableta+ 125 mg/1 tableta filmom obložena tableta Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

clavius 875 mg/1 tableta+ 125 mg/1 tableta filmom obložena tableta

farmis d.o.o. sarajevo - amoksicilin, klavulanska kiselina - filmom obložena tableta - 875 mg/1 tableta+ 125 mg/1 tableta - 1filmom obložena tableta sadrži: 875 mg amoksicilina (u obliku amoksicilin trihidrata) 125 mg klavulanske kiseline (u obliku kalijevog klavulanata)

KlavoPhar 875 mg/1 tableta+ 125 mg/1 tableta filmom obložena tableta Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

klavophar 875 mg/1 tableta+ 125 mg/1 tableta filmom obložena tableta

pharmas d.o.o. sarajevo - amoksicilin, klavulanska kiselina - filmom obložena tableta - 875 mg/1 tableta+ 125 mg/1 tableta - 1 filmom obložena tableta sadrži: 875 mg amoksicilin (u obliku amoksicilin trihidrata) 125 mg klavulonska kiselina (u obliku kalijevog klavulanata)

Nyxthracis (previously Obiltoxaximab SFL) Europska Unija - hrvatski - EMA (European Medicines Agency)

nyxthracis (previously obiltoxaximab sfl)

sfl pharmaceuticals deutschland gmbh - nyxthracis - anthrax - imuni serumi i homologna, - obiltoxaximab sfl is indicated in combination with appropriate antibacterial drugs in all age groups for treatment of inhalational anthrax due to bacillus anthracis (see section 5. obiltoxaximab sfl is indicated in all age groups for post-exposure prophylaxis of inhalational anthrax when alternative therapies are not appropriate or are not available (see section 5.

Palforzia Europska Unija - hrvatski - EMA (European Medicines Agency)

palforzia

aimmune therapeutics ireland limited - defatted powder of arachis hypogaea l., semen (peanuts) - peanut hypersensitivity - allergens - palforzia is indicated for the treatment of patients aged 4 to 17 years with a confirmed diagnosis of peanut allergy. palforzia may be continued in patients 18 years of age and older. palforzia should be used in conjunction with a peanut-avoidant diet.

Dimethyl fumarate Teva Europska Unija - hrvatski - EMA (European Medicines Agency)

dimethyl fumarate teva

teva gmbh - dimetil fumarat - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunosupresivi - dimethyl fumarate teva is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

Dimethyl fumarate Accord Europska Unija - hrvatski - EMA (European Medicines Agency)

dimethyl fumarate accord

accord healthcare s.l.u. - dimetil fumarat - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunosupresivi - dimethyl fumarate accord is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

Ebglyss Europska Unija - hrvatski - EMA (European Medicines Agency)

ebglyss

almirall, s.a. - lebrikizumab - dermatitis, atopic - ostali dermatološki pripravci - ebglyss is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg who are candidates for systemic therapy.